Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Invested Capital: 2009-2022

Historic Invested Capital for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $123.8 million.

  • Avadel Pharmaceuticals' Invested Capital fell 48.64% to $123.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $123.8 million, marking a year-over-year decrease of 48.64%. This contributed to the annual value of $220.6 million for FY2021, which is 24.04% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Invested Capital of $123.8 million as of Q3 2022, which was down 5.49% from $131.0 million recorded in Q2 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Invested Capital ranged from a high of $307.0 million in Q2 2020 and a low of $89.7 million during Q2 2018.
  • For the 3-year period, Avadel Pharmaceuticals' Invested Capital averaged around $227.6 million, with its median value being $241.0 million (2021).
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 2,282.43% in 2018, then slumped by 49.75% in 2022.
  • Avadel Pharmaceuticals' Invested Capital (Quarterly) stood at $118.6 million in 2018, then decreased by 22.03% to $92.5 million in 2019, then surged by 214.07% to $290.5 million in 2020, then declined by 24.04% to $220.6 million in 2021, then slumped by 48.64% to $123.8 million in 2022.
  • Its Invested Capital stands at $123.8 million for Q3 2022, versus $131.0 million for Q2 2022 and $197.9 million for Q1 2022.